204 related articles for article (PubMed ID: 12738719)
1. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
[TBL] [Abstract][Full Text] [Related]
12. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
[TBL] [Abstract][Full Text] [Related]
13. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
[TBL] [Abstract][Full Text] [Related]
14. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
16. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
[TBL] [Abstract][Full Text] [Related]
18. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
19. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
[TBL] [Abstract][Full Text] [Related]
20. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Dowlati A; Robertson K; Radivoyevitch T; Waas J; Ziats NP; Hartman P; Abdul-Karim FW; Wasman JK; Jesberger J; Lewin J; McCrae K; Ivy P; Remick SC
Clin Cancer Res; 2005 Nov; 11(21):7938-44. PubMed ID: 16278419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]